By the time cancer is discovered, it’s often too late to change its course. Close to half of cancers will already have spread, making death — whether within months, five years, or ten years — a near certainty.
Mammograms, colonoscopies, and other cancer screenings may have caught some. But medicine doesn’t screen for many cancers — though in the future, it’s likely we will be able to with a simple blood draw. Biotech companies are working to develop what are known as liquid biopsies, tests designed to detect dozens of different cancers. Studies suggest some of these tests can even find aggressive cancers when they’re still constrained and likely curable, saving hundreds of thousands of lives. Two such tests — made by Grail and StageZero Life Sciences — are already available directly to patients as screening tools. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/2021/12/02/liquid-biopsy-cancer-grail-galleri-stagezero/
